_Drugs_Market.JPG)
Ischemic Heart Disease (IHD) Drugs Market Size was valued at USD 6.07 Bn in 2023 and is predicted to reach USD 8.46 Bn by 2031 at a 4.4% CAGR during the forecast period for 2024-2031.
Ischemic heart disease (IHD) drugs are those that treat situations where the heart does not receive enough blood, most often because the coronary arteries are too small or too clogged. Some of these medications can alleviate chest pain, lower cholesterol, reduce the chance of blood clots, and lessen the workload on the heart, all of which contribute to better heart function and a lower risk of heart attacks. The rising incidence of cardiovascular disorders is driving market growth for ischemic heart disease (IHD) drugs. An important factor driving the growth of the ischemic heart disease market is the rising prevalence of IHD.
Ischemic heart disease is a rapidly expanding industry because of the increasing global mortality rate and the high incidence of chronic disorders, which increase the risk of cardiovascular diseases. Another factor impacting the ischemic heart disease (IHD) drugs market is the recent uptick in the development of more effective medications for the condition, as well as government programs aimed at raising public knowledge about the disease and providing financial support for its diagnosis, treatment, and research. Additionally, throughout the projected time frame, the ischemic heart disease market would see lucrative prospects brought about by technical advancements and product developments.
However, the market growth is hampered by the high-cost ischemic heart disease (IHD) drugs; new IHD drugs are expensive and subject to stringent regulatory authorization. Ischemic heart disease (IHD) medication sales were hit hard by the COVID-19 pandemic, which cut off supply lines and reduced healthcare access for patients. The market growth for IHD was hindered as a result of lower rates of diagnosis and treatment due to the focus on COVID-related treatments. However, when healthcare systems started to get back on their feet, the market started to rise again because people started to pay more attention to managing chronic diseases and the growth of the ischemic heart disease (IHD) drugs industry in the coming years.
The ischemic heart disease (IHD) drugs market is segmented based on disease and drug class. Based on disease, the market is segmented into angina pectoris and myocardial infarction. By drug class, the market is segmented into anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, ACE inhibitors, ARBs, vasodilators, and antithrombotic agents.
The myocardial infarction in ischemic heart disease (IHD) drugs market is expected to hold a major global market share in 2023 because myocardial infarction is on the rise around the world, and one major reason for this is the epidemic of lifestyle-related risk factors like obesity, hypertension, and diabetes. Heart disease is more common among the elderly, which means there will be a greater need for myocardial infarction therapies in the future. The availability of medicines and the quality of life for people with myocardial infarction have both been enhanced by the development of more effective medications made possible by developments in medical technology and research.
ACE inhibitors segment is growing rapidly because of their demonstrated effectiveness in lowering blood pressure and safeguarding cardiac function, thus decreasing the likelihood of cardiovascular disasters. Also pushing for their broad use are recommendations in guidelines for individuals with significant cardiovascular risk, heart failure, and hypertension, especially in countries like the US, Germany, the UK, China, and India.
The North American ischemic heart disease (IHD) drugs market is expected to register the highest market share in revenue in the near future. It can be attributed to a large number of pharmaceutical businesses, academic institutions, and healthcare facilities in the area currently being involved in the study and creation of interventions for heart failure. So, new and improved treatments for ischemic heart disease are now available, and high and rising healthcare expenditure and an advanced healthcare infrastructure.
In addition, Asia Pacific is projected to grow rapidly in the global ischemic heart disease (IHD) drugs market due to available reimbursements, major market players associated with the treatments, and many registered clinical trials. Another element that is anticipated to assist in expanding market growth in this region is the major focus on government funding and reforms.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 6.07 Bn |
|
Revenue Forecast In 2031 |
USD 8.46 Bn |
|
Growth Rate CAGR |
CAGR of 4.4% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Disease, By Drug Class and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Ischemic Heart Disease (IHD) Drugs Market Snapshot
Chapter 4. Global Ischemic Heart Disease (IHD) Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Disease Estimates & Trend Analysis
5.1. by Disease & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Disease:
5.2.1. Angina Pectoris
5.2.2. Myocardial Infarction
Chapter 6. Market Segmentation 2: by Drug Class Estimates & Trend Analysis
6.1. by Drug Class & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Drug Class:
6.2.1. Anti-Dyslipidemic Drugs
6.2.2. Calcium Channel Blockers
6.2.3. Beta-Blockers
6.2.4. ACE Inhibitors
6.2.5. ARBs
6.2.6. Vasodilators
6.2.7. Antithrombotic Agents
Chapter 7. Ischemic Heart Disease (IHD) Drugs Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2019-2031
7.1.2. North America Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2019-2031
7.1.3. North America Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.2. Europe
7.2.1. Europe Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2019-2031
7.2.2. Europe Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2019-2031
7.2.3. Europe Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2019-2031
7.3.2. Asia Pacific Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2019-2031
7.3.3. Asia Pacific Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.4. Latin America
7.4.1. Latin America Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2019-2031
7.4.2. Latin America Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2019-2031
7.4.3. Latin America Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2019-2031
7.5.2. Middle East & Africa Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2019-2031
7.5.3. Middle East & Africa Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Bayer AG
8.2.2. Eli Lilly and Company
8.2.3. Novartis International AG
8.2.4. Pfizer, Inc.
8.2.5. Sanofi S.A.
8.2.6. Actelion Pharmaceuticals Ltd.
8.2.7. Baxter International Inc.
8.2.8. Boehringer Ingelheim International GmbH
8.2.9. Bristol-Myers Squibb Company
8.2.10. Amgen Inc.
8.2.11. F. Hoffmann-La Roche AG
8.2.12. Other Prominent Players
Ischemic Heart Disease (IHD) Drugs Market- By Disease
Ischemic Heart Disease (IHD) Drugs Market- By Drug Class
Ischemic Heart Disease (IHD) Drugs Market- By Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
